BridgeBio Pharma Return on Equity

BridgeBio Pharma (BBIO) currently reports a ROE of 34.3%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore BridgeBio Pharma's ROE history and peer comparisons.

BridgeBio Pharma's ROE of 34.3% is higher than the Healthcare sector average of 13.26%. That is roughly 158.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but BridgeBio Pharma's current 34.3% should be judged against Healthcare norms (sector average: 13.26%) and against BBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 34.3%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On ROE, it currently shows 34.3% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.